PPP

PROBIOTEC LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪239.09 M‬AUD
‪11.02 M‬AUD
‪214.03 M‬AUD
‪45.04 M‬
Beta (1Y)
0.60

About PROBIOTEC LIMITED

CEO
Wesley Stringer
Headquarters
Melbourne
Founded
1997
ISIN
AU000000PBP7
FIGI
BBG000Q5HQV9
Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. It operates through the following segments: Branded Pharmaceuticals, Contract Manufacturing, Obesity and Weight Management, Europe, and Specialty Products. The Branded Pharmaceuticals segment involves the sale of branded pharmaceutical products. The Contract Manufacturing segment involves the contract manufacturing of pharmaceutical, food and animal nutrition products on behalf of domestic and international pharmaceutical and food companies. The Obesity and Weight Management segment is involved in the manufacture and sale of a range of products across a number of channels including FMCG, pharmacy, health food stores and online. The Europe segment is involved in the manufacture and sale of products within Europe. The Specialty Products segment involves in the sale of human and animal nutrition products, incorporating the sale of ingredients and additives for use in the pharmaceutical and food industries. The company was founded in 1997 and is headquartered in Melbourne, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PBP is 2.94 AUD — it has decreased by 0.68% in the past 24 hours. Watch PROBIOTEC LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange PROBIOTEC LIMITED stocks are traded under the ticker PBP.
PBP stock has risen by 0.68% compared to the previous week, the month change is a 3.52% rise, over the last year PROBIOTEC LIMITED has showed a 17.60% increase.
We've gathered analysts' opinions on PROBIOTEC LIMITED future price: according to them, PBP price has a max estimate of 3.00 AUD and a min estimate of 3.00 AUD. Watch PBP chart and read a more detailed PROBIOTEC LIMITED stock forecast: see what analysts think of PROBIOTEC LIMITED and suggest that you do with its stocks.
PBP reached its all-time high on May 13, 2024 with the price of 2.97 AUD, and its all-time low was 0.15 AUD and was reached on Apr 1, 2015. View more price dynamics on PBP chart.
See other stocks reaching their highest and lowest prices.
PBP stock is 1.02% volatile and has beta coefficient of 0.60. Track PROBIOTEC LIMITED stock price on the chart and check out the list of the most volatile stocks — is PROBIOTEC LIMITED there?
Today PROBIOTEC LIMITED has the market capitalization of ‪239.09 M‬, it has decreased by 0.70% over the last week.
Yes, you can track PROBIOTEC LIMITED financials in yearly and quarterly reports right on TradingView.
PROBIOTEC LIMITED is going to release the next earnings report on Aug 21, 2024. Keep track of upcoming events with our Earnings Calendar.
PBP net income for the last quarter is ‪3.13 M‬ AUD, while the quarter before that showed ‪5.56 M‬ AUD of net income which accounts for −43.71% change. Track more PROBIOTEC LIMITED financial stats to get the full picture.
PROBIOTEC LIMITED dividend yield was 2.32% in 2023, and payout ratio reached 47.97%. The year before the numbers were 2.44% and 32.16% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PROBIOTEC LIMITED EBITDA is ‪34.61 M‬ AUD, and current EBITDA margin is 16.25%. See more stats in PROBIOTEC LIMITED financial statements.
Like other stocks, PBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PROBIOTEC LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PROBIOTEC LIMITED technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PROBIOTEC LIMITED stock shows the buy signal. See more of PROBIOTEC LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.